+ Watch OCLS
on My Watchlist
The Company has developed and it manufactures and markets, a family of products intended to prevent and treat infections in chronic and acute wounds.
Amazing new products in the medical field.
Agree! Efficacy of Microcyn appears to be amazing. With August 2010 approval of dermatology gel in Mexico and the beginning of sale of that product there in Sept 10 as well as in USA, the potential in that $3.2 billion mkt should kick the stock price up significantly. Looking at its over all potential in the medical industry, I see nothing but good things for OCLS, its customers and shareholders.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions